| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3989253 | Journal of Thoracic Oncology | 2015 | 8 Pages |
Abstract
Treatment of LC with EGFR TKI, cytotoxic chemotherapy, or WBRT in selected patients is associated with prolong survival period. These treatment options, especially EGFR TKIs, should be studied in patients with EGFR mutation-positive NSCLC and LC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Bin-Chi MD, Jih-Hsiang MD, Chia-Chi Lin, Ya-Fang MD, Chin-Hao PhD, Chao-Chi MD, PhD, Jin-Yuan MD, PhD, Chong-Jen MD, PhD, James Chih-Hsin MD, PhD,